{"id":667183,"date":"2023-09-11T19:30:02","date_gmt":"2023-09-11T19:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=667183"},"modified":"2023-09-11T19:30:02","modified_gmt":"2023-09-11T19:30:02","slug":"familial-adenomatous-polyposis-market-poised-for-extraordinary-growth-during-the-forecast-period-202332-asserts-delveinsight-emtora-sla-pharma-janssen-cellix-bio-zikani-therapyx-funpep","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/familial-adenomatous-polyposis-market-poised-for-extraordinary-growth-during-the-forecast-period-202332-asserts-delveinsight-emtora-sla-pharma-janssen-cellix-bio-zikani-therapyx-funpep_667183.html","title":{"rendered":"Familial Adenomatous Polyposis Market Poised for Extraordinary Growth During the Forecast Period (2023-32), Asserts DelveInsight | Emtora, SLA Pharma, Janssen, Cellix Bio, Zikani, TherapyX, FunPep"},"content":{"rendered":"
\n
\"Familial<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Familial Adenomatous Polyposis Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Familial Adenomatous Polyposis and the launch of new therapies in the market.<\/div>\n

DelveInsight’s “Familial Adenomatous Polyposis Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Familial Adenomatous Polyposis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Familial Adenomatous Polyposis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Familial Adenomatous Polyposis treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Familial Adenomatous Polyposis: An Overview<\/strong><\/p>\n

Familial Adenomatous Polyposis (FAP) is a genetic condition. It is diagnosed when a person develops more than 100 adenomatous colon polyps. An adenomatous polyp is an area where normal cells that line the inside of a person’s colon and from a mass on the inside of the intestinal tract. On average, polyps develop in people with FAP in the mid-teens. Most people with FAP will have multiple colon polyps by age 35. If FAP is not recognized and treated, there is a very high likelihood that a person will develop colorectal cancer.<\/p>\n

Individuals with FAP also have an increased chance of developing cancer in other organs, including the stomach, small intestine, and the pancreas and biliary tree. The risk for hepatoblastoma, a type of liver cancer, is increased in children with FAP. Desmoid tumors\/desmoid fibromatosis, a locally aggressive tumor that does not spread (metastasize), and a type of brain tumor called medulloblastoma can also occur in some individuals. The risk for papillary thyroid cancer is also increased.<\/p>\n

Not all symptoms of FAP are cancer-related. Some additional features of FAP may include: osteomas (noncancerous bony growths, usually found on the jaw), extra, missing, or unerupted teeth, congenital hypertrophy of the retinal pigment epithelium (CHRPE), which is an eye condition that is present at birth that does not affect vision, but it is a condition that an eye physician may see during an examination with a special instrument called an ophthalmoscope. Benign (noncancerous) skin changes, such as epidermoid cysts and fibromas, and adrenal masses, are also typical symptoms of FAP.<\/p>\n

There are four subtypes of familial adenomatous polyposis, namely, Classic familial adenomatous polyposis, Attenuated familial adenomatous polyposis (AFAP), Gardner syndrome, and Turcot syndrome.<\/p>\n

Familial Adenomatous Polyposis Market Key Facts<\/strong><\/p>\n